178 related articles for article (PubMed ID: 3914174)
1. [Interferon in the treatment of multiple myeloma].
Kuzmits R; Ludwig H; Cortelezzi A; Van Camp BG; Polli E; Flener R; Scheithauer W
Acta Med Austriaca; 1985; 12(5):135-8. PubMed ID: 3914174
[TBL] [Abstract][Full Text] [Related]
2. Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial.
Scheithauer W; Cortelezzi A; Fritz E; Kührer I; Polli E; Baldini L; Ludwig H
J Biol Response Mod; 1989 Apr; 8(2):109-15. PubMed ID: 2659740
[TBL] [Abstract][Full Text] [Related]
3. Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial.
Ludwig H; Cortelezzi A; Scheithauer W; Van Camp BG; Kuzmits R; Fillet G; Peetermans M; Polli E; Flener R
Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1111-6. PubMed ID: 3536528
[TBL] [Abstract][Full Text] [Related]
4. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
[TBL] [Abstract][Full Text] [Related]
5. [Results of polychemotherapy (a VMCP/VCAP program) in multiple myeloma].
Wutke K; Anger G
Z Gesamte Inn Med; 1983 Dec; 38(23):630-3. PubMed ID: 6689459
[TBL] [Abstract][Full Text] [Related]
6. [Possibility of using interferon in the treatment of multiple myeloma].
Piatkowska-Jakubas B; Skotnicki AB; Blicharski J
Przegl Lek; 1988; 45(10):747-50. PubMed ID: 3072590
[No Abstract] [Full Text] [Related]
7. VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma.
Preis P; Scheithauer W; Fritz E; Zielinski C; Kuehrer I; Cortelezzi A; Polli E; Baldini L; Pirker R; Kriegisch A
Onkologie; 1989 Feb; 12(1):27-9. PubMed ID: 2654788
[TBL] [Abstract][Full Text] [Related]
8. Human leukocyte interferon and intermittent high-dose melphalan-prednisone administration in the treatment of multiple myeloma: a randomized clinical trial from the Myeloma Group of Central Sweden.
Ahre A; Björkholm M; Mellstedt H; Brenning G; Engstedt L; Gahrton G; Gyllenhammar H; Holm G; Johansson B; Järnmark M
Cancer Treat Rep; 1984 Nov; 68(11):1331-8. PubMed ID: 6388832
[TBL] [Abstract][Full Text] [Related]
9. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
[TBL] [Abstract][Full Text] [Related]
10. A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma.
Nagura E; Ichikawa A; Kamiya O; Kato R; Utsumi M; Tanaka M; Takeyama H; Shimizu K; Kobayashi M; Naito K; Nishiwaki H; Mizuno H; Hirabayashi N; Nitta M; Kato Y; Shibata T; Hotta T; Kawashima K; Saito H
Cancer Chemother Pharmacol; 1997; 39(4):279-85. PubMed ID: 9025767
[TBL] [Abstract][Full Text] [Related]
11. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
Barlogie B; Kyle RA; Anderson KC; Greipp PR; Lazarus HM; Hurd DD; McCoy J; Moore DF; Dakhil SR; Lanier KS; Chapman RA; Cromer JN; Salmon SE; Durie B; Crowley JC
J Clin Oncol; 2006 Feb; 24(6):929-36. PubMed ID: 16432076
[TBL] [Abstract][Full Text] [Related]
12. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma].
Le Loët X; Monconduit M; Menard JF; Deshayes P; Grobois B; Tanguy A; Prevost E; Piguet H
Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189
[TBL] [Abstract][Full Text] [Related]
13. Phase III study of intermittent carmustine (BCNU), cyclophosphamide, and prednisone versus intermittent melphalan and prednisone in myeloma.
Abramson N; Lurie P; Mietlowski WL; Schilling A; Bennett JM; Horton J
Cancer Treat Rep; 1982 Jun; 66(6):1273-7. PubMed ID: 7044535
[TBL] [Abstract][Full Text] [Related]
14. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
Ludwig H; Cohen AM; Huber H; Nachbaur D; Jungi WF; Senn H; Günczler P; Schüller J; Eckhardt S; Seewann HL
Eur J Cancer; 1991; 27 Suppl 4():S40-5. PubMed ID: 1799476
[TBL] [Abstract][Full Text] [Related]
15. Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
Cooper MR; Fefer A; Thompson J; Case DC; Kempf R; Sacher R; Neefe J; Bickers J; Scarffe JH; Spiegel R
Cancer Treat Rep; 1986 Apr; 70(4):473-6. PubMed ID: 3698041
[TBL] [Abstract][Full Text] [Related]
16. [Polychemotherapy versus melphalan-prednisone in multiple myeloma].
Leoni P; Salvi A; Brianzoni MF; Centurioni R; Montillo M; Olivieri A
G Clin Med; 1986 Dec; 67(5-6):291-6. PubMed ID: 3609590
[No Abstract] [Full Text] [Related]
17. Treatment with recombinant interferon-alpha-2C: multiple myeloma and thrombocythaemia in myeloproliferative diseases.
Ludwig H; Cortelezzi A; Van Camp BG; Polli E; Scheithauer W; Kuzmits R; Linkesch W; Gisslinger H; Sinzinger H; Fritz E
Oncology; 1985; 42 Suppl 1():19-25. PubMed ID: 4080297
[TBL] [Abstract][Full Text] [Related]
18. Results and further perspectives of plasmocytoma chemotherapy.
Sakalová A; Hrubisko M; Gazová S; Steruská M; Prümmerová J
Neoplasma; 1986; 33(2):251-8. PubMed ID: 3520353
[TBL] [Abstract][Full Text] [Related]
19. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
[TBL] [Abstract][Full Text] [Related]
20. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
